Abstracts tagged "Disease Activity and rheumatic disease"

Abstract Number: 2253 • 2017 ACR/ARHP Annual Meeting
Patient’s Self-Monitoring of Disease Activity of Rheumatic Diseases Via Webapp – Study Design, Patient’s Perspective and Recruitment in the First 16 Months of a Swiss Multicentre, Longitudinal Study
Veronika K. Jaeger¹, Anna Barmet¹, Pia Schiffer², Pascal Zufferey³, Andrea Badaracco⁴, Marcel Walder⁵, Jean Dudler⁶, Dieter Frey⁷, Franziska Müller¹, Lilian Pichler¹, Peter Voss¹, Lorenzo Bosia⁸ and Ulrich A. Walker¹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Praxis beim Rathaus, Zofingen, Switzerland, ³Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁴Studio Medico Badaracco Cattaneo, Lugano, Switzerland, ⁵Praxis Walder, Dübendorf, Switzerland, ⁶Hôpital Cantonal Fribourg, Fribourg, Switzerland, ⁷Praxis Frey, Basel, Switzerland, ⁸Praxis Bosia, Locarno, Switzerland
Background/Purpose: The management of patients with rheumatic diseases is partly guided by the medical history at each clinic visit. Patients however often find it difficult…
Abstract Number: 1407 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trackers to Support Treat to Target Strategies: A Needs Assessment Survey
Boulos Haraoui¹, Majed M. Khraishi², May Shawi³ and Meagan Rachich⁴, ¹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ²Nexus Clinical Research, St Johns, NF, Canada, ³Janssen Inc, Toronto, ON, Canada, ⁴Medical Affairs, Janssen, Toronto, ON, Canada
Background/Purpose: Custom-built software applications (apps) have become an integral part of medical practice today to help physicians be more efficient. They are being widely used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].